EDIT NASDAQ
Credit Risk of going bust: higher than 56% of companies Debt: 4.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 99.3%), Editas Medicine, Inc. would be worth roughly what it owes.
Total debt $15.5M against a stock market value of $368.6M.
Distance to default 4.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.8M (short-term plus half of long-term), stock volatility 81.2%; Altman Z'' -20.04. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Cambridge, MA 02141
US
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Ory Daniel Scott | A-Award | 950,000 | $3.03 | 2026-09-08 |
| Ory Daniel Scott | 0 | — | 2026-09-08 | |
| Burkly Linda | S-Sale | 709 | $3.04 | 2026-09-03 |
| Parison Amy | S-Sale | 453 | $3.04 | 2026-09-03 |
| O'Neill Gilmore Neil | S-Sale | 5,124 | $3.04 | 2026-09-03 |